Apontis Pharma AG provided revenue guidance for the year 2023. For the year, the company expects revenues of EUR 42.6 million (previously: EUR 51.7 million). The reasons for the changes in forecast revenues and earnings include uncertainties in the supply of the product.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
8.72 EUR | +1.40% |
|
-1.36% | +83.58% |
Jun. 27 | Apontis Pharma AG Appoints Thomas Zimmermann to the Management Board, Effective 1 July 2024 | CI |
Apr. 05 | Apontis Bags Distribution Deal with Novartis Unit for Two Asthma Medications | MT |
![Consensus](/images/consensus_flch.gif)
EPS Revisions
Quarterly revenue - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
+83.58% | 79.28M | |
+63.05% | 856B | |
+39.42% | 631B | |
-4.78% | 359B | |
+17.52% | 325B | |
+8.43% | 297B | |
+14.19% | 244B | |
+5.81% | 234B | |
+16.77% | 226B | |
+14.63% | 177B |
- Stock Market
- Equities
- APPH Stock
- News Apontis Pharma AG
- Apontis Pharma Ag Provides Revenue Guidance for the Year 2023